4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑
4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑
4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 性质
| 熔点 | 124℃ |
|---|---|
| 沸点 | 611.8±65.0 °C(Predicted) |
| 密度 | 1.14±0.1 g/cm3(Predicted) |
| 储存条件 | Store at RT |
| 溶解度 | 乙醇中≤10mg/ml；DMSO 中≤5mg/ml；二甲基甲酰胺中≤2mg/ml |
| 酸度系数(pKa) | 14.37±0.10(Predicted) |
| 形态 | 黄色粉末 |
| 颜色 | 浅黄至黄色 |
| InChI | 1S/C27H24FN3O/c28-24-13-11-22(12-14-24)26-27(23-15-17-29-18-16-23)31(25(30-26)10-4-5-20-32)19-6-9-21-7-2-1-3-8-21/h1-3,7-8,11-18,32H,5-6,9,19-20H2 |
| InChIKey | QSUSKMBNZQHHPA-UHFFFAOYSA-N |
| SMILES | OCCC#CC1=NC(C2=CC=C(F)C=C2)=C(C3=CC=NC=C3)N1CCCC4=CC=CC=C4 |
4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 用途与合成方法
|
p38α 1 μM (IC 50 ) |
p38β 11 μM (IC 50 ) |
RWJ-67657 inhibits the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells with an IC
50
of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B, with an IC
50
value of 13 nM.
RWJ67657 (10 μM; 24 hours) decreases colony formation in MCF-7 cells.
Cell Proliferation Assay
| Cell Line: | MCF-7 breast carcinoma cells |
| Concentration: | 10 μM |
| Incubation Time: | 24 hours |
| Result: | Decreased colony formation. |
RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration.
RWJ-67657 (50 mg/kg; administered orally; once per day for 7 consecutive days) displays a potent anti-inflammatory effect. By both improving the functioning of endothelial progenitor cells (EPCs) and reducing inflammation, EPC transplantation plus RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis after diabetic stroke.
| Animal Model: | The db/db mice (male, 8 weeks old) with EPCs |
| Dosage: | 50 mg/kg |
| Administration: | Administered orally; once per day for 7 consecutive days |
| Result: | Increased angiogenesis and neurogenesis of diabetic mice after cotreatment with EPCs transplantation. |
4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-15505R | 4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 | 215303-72-3 | 5 mg | 1750 |
| 2026-09-15 | HY-15505R | 4-(4-氟苯基)-2-(4-羟基-1-丁炔)-1-(3-苯基丙基)-5-(4-吡啶基)咪唑 | 215303-72-3 | 10 mg | 2800 |
